Pfizer

Contact
pfizer.com
+1-212-733-2323

Pfizer Inc.

235 East 42nd Street
10017 New York City
USA
+1-212-733-2323
pfizer.com
Contact
Profile News
Contact

About Pfizer

Breakthroughs That Change Patients' Lives: Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend and significantly improve lives. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Read more about Pfizer
Facts about Pfizer
  • Focus : Manufacturer
  • Industry : Pharma

News about Pfizer

Pfizer

11-Jul-2024 | research and development

Evotec and Pfizer collaborate to advance drug discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases

Read news
Pfizer

25-Oct-2022 | business & finance

Anokion Announces $35 Million Equity Investment from Pfizer

Funding Supports Advancement of KAN-101 for Celiac Disease into Phase 2 Clinical Development

Read news
Pfizer

20-Jun-2022 | business & finance

Pfizer will invest €90.5 million in Valneva

Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15

Read news
Pfizer

30-Sep-2021 | research and development

Pfizer Starts Study of mRNA-Based Next Generation Flu Vaccine Program

The mRNA technology could to improve upon the efficacy of current flu vaccines

Read news
Pfizer

24-Aug-2021 | research and development

FDA Approves First COVID-19 Vaccine

The U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now ...

Read news
Pfizer

03-Mar-2021 | business & finance

Iktos Announces Collaboration With Pfizer in AI for Drug Design

“We are proud to work with Pfizer and to have their scientists use our software in their early discovery programs”

Read news
Pfizer

10-Nov-2020 | research and development

Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study

Candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis

Read news
Pfizer

08-Sep-2020 | research and development

BioNTech and Pfizer test COVID-19 Vaccine Candidate in Germany

Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2/3 Trial Received

Read news
Show more news about Pfizer

Here you will find Pfizer Inc.

Last viewed contents

Acute_phase_protein

Go to page